Sagimet Biosciences Inc
F:0O2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sagimet Biosciences Inc
F:0O2
|
US |
|
Koc Holding AS
F:KRKA
|
TR |
|
C
|
China Aerospace International Holdings Ltd
XMUN:CIOC
|
HK |
Intrinsic Value
The intrinsic value of 
Sagimet Biosciences Inc (0O2) under the Base Case is 2.02 EUR per share.
Compared with the current market price of 8.62 EUR, the stock appears
Overvalued by 77% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Sagimet Biosciences Does
Sagimet Biosciences is a drug-development company focused on medicines that block fatty acid synthase, an enzyme tied to fat production in the body. Its lead program is denifanstat, an oral drug candidate being studied for liver disease and severe acne. The company does not sell a broad consumer product line; it develops prescription drug candidates and works to move them through clinical testing and regulatory approval.
- Headquarters
- United States of America US
- Employees
- 16
- IPO date
- Jul 14, 2023
Earnings Waterfall
Sagimet Biosciences Inc
The intrinsic value for Sagimet Biosciences Inc (0O2) under the Base Case is 2.02 EUR.
Compared with the current market price of 8.62 EUR, the stock appears Overvalued by 77% .